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Background: It has been shown that rod-mediated dark adaptation is significantly delayed in 
ageing, a change which is exacerbated in age-related macular degeneration. Levels of lutein 
and zeaxanthin, the two main constituents of macular pigment have been found in rod outer 
segments, indicating that the macular pigment may have an influence on rod-mediated dark 
adaptation. The aim of this study was to determine if rod-mediated dark adaptation is associated 
with central macular pigment levels in individuals with intermediate stage age-related macular 
degeneration. 
 
Methods: A cross sectional observational study included individuals with acuity better than 6/15 
Snellen and intermediate stage age-related macular degeneration based on graded fundus 
photographs using an internationally accepted grading scale. Rod-mediated dark adaptation 
was assessed at five degrees eccentricity in the superior retina (inferior visual field) using the 
rod intercept time measure from the MacuLogix AdaptDx. Macular pigment optical density was 
measured at 0.5 degrees eccentricity using a heterochromatic flicker photometry-based method. 
 
Results: Twenty-seven individuals (mean age 76.7 years) with intermediate stage age-related 
macular degeneration and twenty-three age-matched normal controls (mean age 74.0 years) 
were recruited. Rod-mediated dark adaptation was significantly delayed in intermediate stage 
age-related macular degeneration compared with healthy controls (32.9 mins versus 10.7 mins, 
p<0.01). There was no statistically significant correlation between the rod intercept time and the 
level of macular pigment in those with intermediate age-related macular degeneration (r= -.04, 
p=0.85).  
 
Conclusion:   The results did not support the hypothesis that higher macular pigment is 
associated with improved rod-mediated performance or that higher levels of macular pigment 



















One extremely informative measure of visual function in the ageing eye is the dark adaptation 
curve, which is a measure of the ability of the eye to adapt to the dark after the retina has been 
bleached with a bright light.1 The dark adaptation curve has two basic components, the first is 
cone mediated and the second is rod mediated. The curve displays significant changes in the 
healthy ageing eye, 2 that are exacerbated in age-related macular degeneration (AMD). 3-10 
Almost all studies with AMD participants have shown that rod mediated dark adaptation (RMDA) 
is significantly increased in comparison to age-matched individuals free from disease. This is 
seen in a delayed rod-cone break time and a shallower slope of the rod-mediated portion of the 
curve.4, 6, 8 For examples of this change see Figure 1 in Owsley et al., 2007,4 and Figure 2 in 
Flamendorf et al., 2015.8 It has been postulated that this deficit in RMDA with age and AMD is 
principally caused by impaired translocation of retinoids and other essentials from the choroid 
across the retinal pigment epithelium - Bruch’s membrane sub-retinal space.11 This dysfunction is 
heightened in AMD through the accumulation of drusen and retinal pigment epithelium 
pigmentation changes.11 An age-related deterioration in the optical quality of the eye may also 
contribute to any decline in rod-mediated performance.12, 13 
It is believed that the macular pigment plays a crucial role in the retina as a powerful antioxidant 
and short-wavelength light filter, which may help protect the retinal pigment epithelium and 
photoreceptors from oxidative damage over a lifetime.14 This is of particular interest with regard 
to AMD, as it is hypothesised that one of the primary contributions to this condition is increasing 
retinal pigment epithelium dysfunction with age due to cumulative oxidative damage.15  It has 
been shown that lutein and zeaxanthin, two of three constituents of the macular pigment,  are 
present in significant amounts in the rod outer segments.16, 17 This finding leads to the hypothesis 
that the macular pigment may be involved in helping maintain normal rod physiology and 
subsequent rod-mediated function in ageing. Indeed, Stringham et al (2015) recently reported 
that in a small group (27 participants) of younger healthy individuals both dark adaptation 
recovery time and absolute scotopic thresholds were associated with macular pigment levels 
over a central retinal area.18 Patryas et al. (2014) also found a weak positive association (which 
was not statistically significant) between the slope of S2 and S3 portions of the dark adaptation 
curve at 11 degrees eccentricity and central macular pigment estimates using 33 participants.19 
Conversely however, in a recent study Zarubina et al., 2018 showed in a large sample of healthy 
older individuals (participants=225; mean age 68.2 years) that RMDA was not associated with 
central macular pigment levels. 20 They conclude that such a finding fits with the aforementioned 
vascular-metabolic theory for RMDA increases and query the basis for expecting a relationship 
between RMDA and macular pigment given that the macular pigment level in rod outer segments 
is low relative to the high levels in the foveal centre. However, they do acknowledge that further 





None of these previous studies included participants with any clinical signs of AMD. No 
published information on the relationship between RMDA and macular pigment levels exists 
in individuals with AMD. If RMDA in AMD is associated with macular pigment levels it would be of 
particular interest to clinicians as the macular pigment can potentially be enhanced through 
dietary and lifestyle changes and by supplementation. Indeed, AREDS2 suggested that it may be 
appropriate to replace beta carotene with lutein and zeaxanthin in AREDS type antioxidant 
supplements for those individuals with intermediate AMD.21 
The objective of this study was to establish whether or not RMDA is associated with macular 
pigment levels in intermediate stage AMD patients, who have an increased risk of developing 




This cross-sectional observational study was undertaken at the Vision Science research 
laboratory at the University of Ulster, which is a regional University in the United Kingdom. 
Participants were recruited by advertisement from the public optometry clinic in Ulster University 
and through local advertisement with macular disease support groups and optometry practices. 
Ethical approval for the study was obtained from the University of Ulster Research Ethics 
Committee and informed written consent was obtained from all participants after explanation of 
the nature and possible consequences of the study in accordance with the tenets of the 




Intermediate AMD  
All individuals had a visual acuity of at least 0.40 logMAR (>6/15 Snellen) with best spectacle 
lens correction of between ±6DS and less than 3 DC in the study eye. After the visual function 
testing (described below) was completed, dilated 30° colour fundus photographs centred on the 
macula were taken  (Canon CR-DGi, Uxbridge, UK). Each photograph was examined 
independently by two experienced optometrists to confirm participants had intermediate AMD as 
defined using an internationally accepted grading scale.  23 Intermediate AMD was defined as 
any medium sized drusen (63 to 125µm) with pigmentary abnormalities associated with AMD or 
any large drusen (>125µm) within two disc diameters of the fovea. In addition, all participants 
underwent ocular coherence tomography scanning using the Fast Retinal protocol of the retinal 
application of the Heidelberg Spectralis with TruTrack eye tracking technology (Heidelberg, 
Germany). This is a macular volume scan centred on the fovea with 19 equally separated 





line to reduce noise and enhance resolution. Images were assessed to exclude anyone with any 
other co-existing abnormality, such as epi-retinal membrane or significant vitreomacular traction, 
which could contribute to vision loss other than the intermediate AMD. Participants were excluded 
if they had any other co-existing eye disease (such as glaucoma or diabetic retinopathy) which 
would impact on the findings.  
 
Healthy individuals 
All participants had a best corrected visual acuity of 0.20 logMAR (Snellen 6/9.5) or better in the 
study eye, refractive error between +6DS and -6DS with <3.00DC and normal retinal health 
based on fundus photography and OCT examination. Anyone with amblyopia in the study eye, 
advanced AMD in their fellow eye or a history of systemic conditions which may affect vision 
were excluded. None of the older participants had any visually significant age-related cataract as 
judged on dilated slit-lamp examination.  
 
Visual function 
Monocular logMAR visual acuity was determined, after a full subjective refraction, with a Bailey-
Lovie chart with distance prescription, with credit given for each correct letter read. Monocular 
contrast sensitivity was determined using the Mars Letter Contrast Sensitivity chart (Mars 
Perceptrix, Chappaqua, NY, US). Participants were instructed to read the letter chart, which was 
positioned at 50cm with the appropriate near correction in place, until the letters became 
indistinguishable. The log contrast sensitivity value is determined as the final letter correctly 
identified before the patient misidentifies two consecutive letters, with incorrect responses prior to 
this taken off the final log contrast sensitivity value. For individuals with bilateral intermediate 
AMD the study eye was that with the better logMAR acuity. If acuity was equal in both eyes, then 
the eye with the better contrast sensitivity value was used for testing. 
 
Macular Pigment Optical Density 
Macular pigment optical density was estimated in the study eye at 0.5 degrees from the foveal 
centre using a heterochromatic flicker photometry based densitometer instrument (Macular 
Metrics, Rehoboth, MA, USA) which has been described in detail in several previous 
studies measuring macular pigment in normal, 24, 25 and  AMD patients (using an adapted 
version).26 
Firstly, several practice thresholds were measured to ensure the participant understood the task to 
be performed. Under monocular viewing conditions in a dim room the participant was asked to 
fixate on the centre of a flickering target, a solid 1° diameter target comprised of two 
alternating wavelengths (460nm and 560nm) displayed on a 6° blue background (470nm). The 





threshold to ensure there was clear visible flicker to begin with, until the point where the test target 
appeared stationary, or had minimal flicker. The two wavelengths of light were inversely yoked to 
maintain a constant brightness and threshold was measured using the optimal flicker frequency 
for that individual (measured before thresholds were taken). The task was repeated using a disc 
of 2° in diameter presented at 7° eccentricity from a central red fixation point subtending 5 
minutes of arc. Four thresholds at each retinal location were taken for calculating the macular 
pigment optical density which was calculated using the following formula:  
Macular pigment optical density = Log (R460F/ R460P) – Log (R560F/R560P) where R460 is the 
radiance of the 460 nm light and R560 the radiance of the 560 nm light at the foveal (F) and 




RMDA was assessed with the AdaptDx (MacuLogix, Hummelstown, PA) which measures the rod 
intercept time. This is the time from the onset of a reduced retinal bleach to reach a criterion light 
level on the dark adaptation curve, where vision is completely rod mediated. Those with better 
rod recovery will have a shorter rod intercept time than those with impaired rod function, allowing 
rod-mediated performance to be more easily compared between individuals using one outcome 
parameter. The instrument has been used in several studies looking at rod mediated function in 
healthy individuals and in various stages of AMD.7-10, 27, 28 
For this measure the pupil of each participant’s test eye was dilated to at least 6mm in diameter 
using 0.5% Tropicamide to eliminate the effects of pupil size on the rod intercept time measure. 
Participants were instructed to fixate on a red fixation light located 5 degrees superiorly from the 
centre of the screen for the duration of the test and advised that a single spot stimulus would 
appear directly below this point throughout the test. Patient fixation was assessed throughout 
using an infrared camera which displayed the patients eye on the operating screen. Corrective 
lenses suitable for the 30cm viewing distance were positioned in front of the test eye using the 
built-in lens holder provided by the instrument to correct for optical blur with the other eye being 
covered by an opaque patch. 
A 505nm photoflash (0.8ms duration, 1.8x10
4 scot cd/m
2 intensity) provided a ~76% rod bleach 
equivalent over a 4° area of retina centred at 5° eccentricity directly below the fixation light. 
Threshold sensitivity measurements began immediately after at this location using a 2° 
diameter circular target (wavelength 505nm) with a 3 down/1-up modified staircase estimate 
procedure. Participants were given 2 seconds to respond if the stimulus was visible using a 
response button. Fixation error rate was calculated as a percentage of the number of unreliable 





the total number of thresholds. All individuals had a fixation loss of less than 35% (average fixation 
loss was 14.7%). Testing concluded when the subject’s sensitivity recovered to 5x10-3 scotopic 
cd/m2 (3.0 log units attenuation of the stimulus) determined by the internal software of the 
instrument, as this threshold level is considered to be completely mediated by rod function. 
The test could continue to up to 45 minutes at which point it was terminated if the recovery 
threshold had not been reached (a 45 minute rod intercept time was assigned to those 
participants for statistical analysis).  
 
Statistical analysis 
Statistical analyses were performed with SPSS software version 22 (IBM Corporation, Armonk, 
NY). Macular pigment optical density was measured in log units and the rod intercept time in 
minutes. Shapiro-Wilks tests showed that the macular pigment estimates were normally distributed 
for both groups (p>0.05) but that the rod intercept time in the intermediate AMD group was not 
normally distributed (p<0.05). Differences in age, logMAR acuity, contrast sensitivity and macular 
pigment optical density between the two groups were analysed using independent t tests. 
Correlation between any of these variables was examined using the Pearson correlation co-
efficient (rp). The difference in the rod intercept time between the groups was analysed using the 
Mann-Whitney U test. Correlation between the rod intercept time and any other variable in the 
intermediate stage AMD group was examined using the Spearman’s rank correlation coefficient 
(rs). The study had better than 80% power to detect a large correlation between macular pigment 
optical density and the rod intercept time (r = 0.52 or better) at the 0.05 significance level in the 
intermediate AMD group, which was the primary objective of the study.  
 
RESULTS 
Twenty-seven individuals with intermediate AMD (12 males, 15 females; mean age 76.7 years 
(range 63-88 years)) were recruited to the study. Eight of these individuals had early AMD in 
their fellow eye, while nine had intermediate stage and ten had late stage AMD. Twenty-three 
older individuals free from any ocular disease (10 males, 13 females; mean age 74.0 years 
(range 68-86 years) were recruited for comparison with the AMD group. Two of these individuals 
had early AMD in their fellow eye while all others had no sign of AMD in their fellow eye. Table 
one summarises the visual function measures for those with intermediate stage AMD and the 
normal group. This shows that for the two age-matched groups all measures of visual function 
were significantly poorer in the intermediate AMD group (p<0.05) but that there was no 
statistically significant difference in macular pigment optical density between the two groups 
(p>0.05). When those individuals in the AMD group who were taking any form of supplement 
containing one or more of the retinal carotenoids (number=13) were removed from the analysis 





between the healthy normal group and the intermediate AMD group (0.44 versus 0.41 log 
units; p= 0.62). Smoking status (never a smoker versus previous smoker) did not have any 
statistically significant effect on macular pigment values in either the AMD group (p= 0.23) or the 
normal group (p=0.36).The rod intercept time for the intermediate AMD individuals was, on 
average, three times longer than that of the normal individuals indicating that a significant 
deficit in rod-mediated performance exists (32.9mins versus 10.7 mins). While there was 
significant overlap in logMAR acuity values between the two groups only two intermediate 
AMD individuals had a rod-intercept value which fell within the range of the values found in 
the normative group.  
There was no statistically significant correlation between the rod intercept time and the level of 
macular pigment in either the normal group (rp=-0.16, p= 0.46) or the AMD group (rs= -0.04, p=0.85) 
(Figure One). When the individuals with previous late AMD in the fellow eye were removed 
from the intermediate AMD analysis no statistically significant relationship was found between 
macular pigment optical density and the rod intercept time (rs= -.13, p=0.63). There was no 
statistically significant relationship between the rod intercept time and logMAR acuity in the 
intermediate AMD group (rs= 0.33, p=0.09) however there was a statistically significant 
relationship between the rod intercept time and contrast sensitivity (rs=-0.41, p=0.03).  
The rod intercept time was higher in those individuals who had late-stage AMD in the fellow eye, 
compared those without late AMD in the fellow eye, but this failed to reach statistical significance 
(38.6 versus 29.6 mins; p=0.05). There was no significantly significant difference in acuity, CS or 
age between these two groups (p>0.05 for all). Macular pigment optical density was significantly 
higher in those individuals who had late stage AMD in the fellow eye (0.55 versus 0.40 log units, 
p=0.04). However, eighty percent of those participants who had late-stage AMD in their fellow 
eye took some form of supplementation containing lutein and/or zeaxanthin (in comparison to 
29% of those without late AMD in the fellow eye). 
Eleven individuals reached the maximum rod intercept time of 45 minutes without reaching 
the rod recovery criterion point (seven of these individuals had late AMD in the fellow eye). 
There was no statistically significant difference in macular pigment levels between those who 
reached the maximum time (mean rod intercept time=45 mins, mean macular pigment = 0.45) 
in comparison to all of the other individuals in the AMD group (mean= 24.6mins, mean macular 




Several recent studies have investigated the relationship between RMDA and macular pigment 
levels in healthy individuals free from ocular disease. 18-20 The largest of these three studies 





macular pigment optical density estimated using a heterochromatic flicker photometry based 
instrument.20This current study, using the same retinal locations for RMDA and macular pigment 
measures as Zarubina et al. 2018,  has shown that there is no statistically significant association 
between RMDA and macular pigment in individuals with intermediate stage AMD. In this study 
we minimised any influence age-related optical changes in the eye may have on RMDA by 
dilating all participants, correcting for refractive error and by including only those free from 
cataract. Therefore, the measurement of RMDA using the AdaptDx rod intercept time primarily 
reflects the function of the underlying rod photoreceptors. The rod intercept time measures found 
in this study are similar to those reported in a previous study with AMD participants using similar 
methods.8 
It could be argued that if an individual had a significant amount of macular pigment at 5 degrees 
eccentricity  it could have a detrimental effect on the rod intercept time simply by reducing the 
visibility of the 505nm light due to the spectral absorbance profile of the macular pigment 29. 
However, significant amounts of macular pigment have been measured in only a very small 
percentage of individuals at 5 degrees eccentricity, 30, 31 with the vast majority displaying no 
measurable macular pigment at this retinal location. The very maximum amount of macular 
pigment measured in any individual reported in the literature is less than 0.1 log units at 5 
degrees from the foveal centre 31. Wooten and Hammond, 1992 show that for this level of 
macular pigment there would still be 90% transmittance of the 505nm stimuli for measuring the 
rod intercept time (see Figure 7 in this publication) 32. Therefore, we can be fairly certain that the 
5 degrees location chosen did not inadvertently remove any relationship between these 
functional measures. Although two previous studies in normal individuals used a more eccentric 
retinal location for measuring rod-mediated performance (both beyond 10 degrees 
eccentricity),18, 19 we believe that a more eccentric location for the rod intercept time measure 
would have made the task considerably more difficult for the participants, resulting in less reliable 
measures.  
One assumption of this study is that the single central measure of macular pigment reported in 
this study is an appropriate reflection of the overall level of macular pigment within the retina. 
Although macular pigment has been found in significant amounts in rod outer segments, 16, 17 
most of the macular pigment has been shown to be concentrated in the pre-receptoral Muller 
cells in the foveal centre. This location lends itself more to the idea that the macular pigment may 
have a stronger relationship with cone mediated visual functions, and there is some evidence to 
suggest that this might indeed be the case.33 
As the study included 27 individuals with intermediate AMD we only had sufficient statistical 
power to detect a large correlation (>0.52) between these two measures. However, Figure 1 
suggests that a statistically significant relationship between these two measures would be 





arbitrary rod intercept time threshold scotopic sensitivity within 45 minutes did not have a level of 
macular pigment that was significantly different to those who reached this point in a much faster 
time. Those that reached the arbitrary cut-off rod intercept time also had macular pigment values 
across the whole range measured (0.14-0.85 log units).  
The protective effect of the macular pigment on the risk of developing AMD remains inconclusive 
with evidence for and against this theory. 14, 34, 35 In this study, with a relatively small number of 
participants, there was no significant difference in the amount of macular pigment measured in 
those with intermediate AMD compared to the age-matched healthy individuals. Of course, it 
must be recognised that the control group in this study was simply based on the observation that 
these individuals were free from fundal signs of AMD. We didn’t collect any information on dietary 
intake or assess serum levels of carotenoids. Therefore, it must be considered that the dietary 
intake (and supplement intake) could be significantly different between the two groups hiding any 
true baseline differences in macular pigment levels earlier in life. In addition to this the disease 
process itself may lead to loss of the macular pigment which is not accounted for using such 
methods. Several previous studies have investigated macular pigment levels in various stages of 
AMD and while some have found a significant reduction in macular pigment in AMD patients, 36 
several others have not. 37, 38 Very limited data exists on baseline levels of macular pigment 
levels prior to the clinical appearance of macular degeneration.39 Until substantial data on pre-
disease macular pigment levels is available for individuals who subsequently develop AMD, the 
true impact of the macular pigment on disease risk will continue to be debated. 
In conclusion the results of this study  do not support the hypothesis that higher macular pigment 
is associated with improved rod-mediated performance or that higher levels protect rod-mediated 
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Pseudophakic = 5 
Former smoker =10 
On supplementation with 
lutein or zeaxanthin =3 
Intermediate AMD 
(number=27) 
Pseudophakic = 2 
Former smoker = 7 
On supplementation with 













LogMAR acuity 0.04 (±0.10) 0.17 (±0.13) p= <0.01 
Range: -0.18 - +0.20 Range: -0.06 - +0.40 
  
Contrast sensitivity 1.46 (±0.14) 1.32 (±0.18) p= <0.01 




0.44 (±0.18) 0.45 (±0.20) p= 0.85 
Range: 0.09 – 0.76 Range: 0.14 – 0.85 
  
Rod intercept time 10.7 (±3.2) 32.9 (±11.5) p=<0.01 









Table 1. Participant characteristics  and visual function measures for the normal group 
and those with intermediate AMD. Differences between the two groups was analysed 
using an independent t-test for all variables except the rod intercept time where a Mann- 













Figure 1: Rod intercept time values at 5 degrees eccentricity (superior retina/inferior field) versus 
macular pigment optical density levels at 0.5 degrees eccentricity from the foveal centre for healthy 
normal participants (open circles) and those with intermediate stage AMD (closed circles).Two sets of 
individuals in the intermediate stage AMD group, who all had a rod intercept time of 45 minutes, had 
exactly the same macular pigment optical density values (0.14 and 0.25 log units).There was no 
statistically significant relationship between the two measures in either group (p>0.05) . 
 
 
 
